ARVAX’s strategy is to transform credible longevity science into decisive early human data.
We combine scientific selectivity, operational precision, and regulatory agility to move promising programs from concept to clinic faster and more efficiently than traditional biotech pathways.
We combine scientific selectivity, operational precision, and regulatory agility to move promising programs from concept to clinic faster and more efficiently than traditional biotech pathways.
- Source BreakthroughsWe actively scout early-stage discoveries from universities, biotech startups, and inventors worldwide.
Our focus is on innovations addressing the biological systems of aging — cellular energy, inflammation, and neuroprotection — where translational human data can unlock new therapeutic classes.01 - Select and StructureEvery opportunity undergoes rigorous due diligence: mechanism validation, preclinical data review, CMC readiness, and IP assessment.
Selected programs are structured under the ARVAX Operating System to ensure clean ownership, clear biomarker strategy, and rapid clinical readiness.02 - Translate in ANZUsing Australia and New Zealand’s CTN/CTX regulatory pathways, we design and execute first-in-human trials that meet global GCP standards while benefiting from unmatched speed and capital efficiency.
Our integrated network of ethics committees, CROs, and Phase 1 units allows activation in weeks — not months.03 - Generate Decisive DataEach study is designed around translational biomarkers and clear go/no-go endpoints.
The result is data that informs licensing, co-development, or progression to later-stage trials in the U.S., EU, or Asia.04 - Scale Through PartnershipsWe leverage strategic collaborations with CROs, academic hospitals, and biotech investors to expand successful programs and co-develop new ones.
ARVAX acts as both operator and enabler — ensuring each validated concept moves efficiently toward global impact.05
Our guiding principle:
Longevity innovation must move fast, stay credible, and generate human data that matters.
MENU
CONTACTS
Legal Disclaimer
The information provided on this website is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or investment product. Nothing contained on this site should be interpreted as investment, legal, tax, or other professional advice, and visitors should not rely solely on the information presented herein for making investment or other decisions.
Investments in early-stage biotechnology, vaccines, and preventive medicine companies involve a high degree of risk, including the potential loss of invested capital. Past performance is not indicative of future results, and there can be no assurance that any investment strategy will achieve its objectives.
Any references to portfolio companies, strategic partners, or case studies are provided solely for illustrative purposes and should not be construed as a guarantee of future investment opportunities or performance. Forward-looking statements, projections, or expectations expressed on this site are inherently uncertain and subject to change without notice.
Access to certain investment opportunities is restricted to qualified or accredited investors as defined under applicable securities laws. Visitors should consult with their own legal, financial, and tax advisors before making any investment decisions.
By using this website, you acknowledge and agree that Arvax shall not be liable for any losses or damages arising from reliance on the information contained herein.
This website and its contents are governed by and construed in accordance with the laws of the United Arab Emirates (UAE). Any disputes arising out of or related to the use of this website shall be subject to the exclusive jurisdiction of the courts of the United Arab Emirates.
The information provided on this website is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or investment product. Nothing contained on this site should be interpreted as investment, legal, tax, or other professional advice, and visitors should not rely solely on the information presented herein for making investment or other decisions.
Investments in early-stage biotechnology, vaccines, and preventive medicine companies involve a high degree of risk, including the potential loss of invested capital. Past performance is not indicative of future results, and there can be no assurance that any investment strategy will achieve its objectives.
Any references to portfolio companies, strategic partners, or case studies are provided solely for illustrative purposes and should not be construed as a guarantee of future investment opportunities or performance. Forward-looking statements, projections, or expectations expressed on this site are inherently uncertain and subject to change without notice.
Access to certain investment opportunities is restricted to qualified or accredited investors as defined under applicable securities laws. Visitors should consult with their own legal, financial, and tax advisors before making any investment decisions.
By using this website, you acknowledge and agree that Arvax shall not be liable for any losses or damages arising from reliance on the information contained herein.
This website and its contents are governed by and construed in accordance with the laws of the United Arab Emirates (UAE). Any disputes arising out of or related to the use of this website shall be subject to the exclusive jurisdiction of the courts of the United Arab Emirates.
